Growing Options for R/R Follicular Lymphoma

Jennifer L. Garson, PA-C, gave an overview of follicular lymphoma and how she manages adverse effects in her institution.

Expert oncologists discuss the evolving treatment landscape for follicular lymphoma and highlight key advances that have contributed to improved treatment options.

A panel of experts present that case of a 65-year-old woman with follicular lymphoma and discuss potential approaches for treatment in the relapsed or refractory setting.

An overview of available treatment options for relapsed or refractory follicular lymphoma and with considerations for treatment selection and expert insight on preferred treatment approaches in the second-line setting.

Experts review data updates from the AUGMENT trial and discuss potential clinical implications of these study findings.

Hematologist/oncologists describe the rationale for treatment approaches targeting EZH2 and discuss recent guideline updates surrounding the role of tazemetostat and EZH2 testing in patients with follicular lymphoma.

Faculty highlight recent changes in treatment guidelines surrounding the use of PI3K inhibitors in follicular lymphoma and discuss the evolving role of these agents in the treatment landscape.

Expert oncologists discuss best practices surrounding treatment follow-up and monitoring for patients with relapsed or refractory follicular lymphoma.

Panelists review the previously presented patient case and discuss alternative treatment strategies in early disease progression with expert insight on preferred treatment approaches for this setting.

An overview of the evolving role of CAR-T therapy in patients with relapsed or refractory follicular lymphoma.

Expert oncologists offer considerations for the use of CAR-T therapy and bispecific antibodies in follicular lymphoma and discuss potential challenges that may limit the use of these agents in clinical practice.

Faculty review potential adverse events (AEs) seen in patients receiving treatment with bispecific antibodies and discuss preferred strategies for AE management.

An expert discussion surrounding the evolving treatment landscape for relapsed or refractory follicular lymphoma in the third-line setting and beyond.

Panelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.